Dr Reddys Laboratories Share Price Today (DRREDDY)
TODAY IN ONE LINE
DRREDDY fell 1.1% on above-average volume (1.9x avg), lagging Nifty's 1.1% move.
With a market cap of ₹1.01 L Cr., it trades at a P/E of 24.09. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Dr Reddys Laboratories flags
Key strengths and potential risks.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 19.2%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 86.2% YoY
- ●Sales ContractionQuarterly sales dropped 11.5% YoY
What changed recently?
Recent events, corporate actions, and announcements.
Dr Reddys Laboratories Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Dr Reddys Laboratories Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Dr Reddys Laboratories Ltd trades at a P/E of 24.09× and P/B of 2.67×, against the Healthcare sector median P/E of 39.74×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Dr Reddys Laboratories Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Dr Reddys Laboratories Ltd — derived from the live tape, not yesterday's close.
Dr Reddys Laboratories Ltd last traded at ₹1,211.2 with an intraday range of ₹1,201.2–₹1,229.9 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1211.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1284.40 | +73.20 | +6.04% |
| R3 | 1255.70 | +44.50 | +3.67% |
| R2 | 1242.80 | +31.60 | +2.61% |
| R1 | 1227.00 | +15.80 | +1.30% |
| PIVOT | 1214.10 | 2.90 | 0.24% |
| CURRENT | 1211.20 | — | — |
| S1 | 1198.30 | -12.90 | -1.07% |
| S2 | 1185.40 | -25.80 | -2.13% |
| S3 | 1169.60 | -41.60 | -3.43% |
| S4 | 1140.90 | -70.30 | -5.80% |
DRREDDY is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹1213.2–₹1229.9
Trading Below opening range, showing Bearishness
Dr Reddys Laboratories Ltd financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Dr Reddys Laboratories Ltd — consolidated or standalone — with margins, YoY growth and key ratios inline.
Dr Reddys Laboratories Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1.01 L Cr. and reported EPS of ₹50.30.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 32,644 | 33,700 ▲ 3.2% |
| Sales Growth YoY %Derived | 16.54% | 3.24% |
| Other Income | 1,097 | 1,358 ▲ 23.8% |
| Total Income | 33,741 | 35,059 ▲ 3.9% |
| 9,980 | 12,239 ▲ 22.6% | |
| Gross ProfitDerived | 22,664 | 21,461 ▼ 5.3% |
| Gross Margin %Derived | 69.43% | 63.68% |
| 14,117 | 15,008 ▲ 6.3% | |
| EBITDA (Operating Profit)Derived | 8,547 | 6,454 ▼ 24.5% |
| OPM %Derived | 26.18% | 19.15% |
| 1,987 | 2,433 ▲ 22.5% | |
| Profit Before Tax (PBT) | 7,658 | 5,379 ▼ 29.8% |
| 1,954 | 1,235 ▼ 36.8% | |
| Effective Tax %Derived | 25.52% | 22.96% |
| Total Profit for Period | 5,725 | 4,158 ▼ 27.4% |
| Less: Non-controlling Interests | 70 | -38 ▼ 154.8% |
| Net Profit (Owner's PAT)Derived | 5,655 | 4,196 ▼ 25.8% |
| Net Profit Margin %Derived | 17.32% | 12.45% |
| PAT Growth YoY %Derived | 1.38% | -25.80% |
| Earnings Per Share (EPS ₹) | 67.77 | 50.27 ▼ 25.8% |
| Diluted Shares Outstanding (Cr) | 83 | 83 ▲ 0.0% |
| Share of Profit from Associates/JVs | 22 | 13 ▼ 38.2% |
| Other Comprehensive Income (Net of Tax) | 205 | 740 ▲ 260.9% |
| Total Expenses (incl. D&A & Interest) | 26,083 | 29,679 ▲ 13.8% |
| Material Cost % of RevenueDerived | 17.41% | 19.29% |
| Employee Cost % of RevenueDerived | 17.09% | 17.78% |
| Other Cost % of RevenueDerived | 26.15% | 26.76% |
| Interest Coverage (x)Derived | 24.19x | 11.76x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 14,281 | 15,448 ▲ 8.2% | 17,517 ▲ 13.4% | 19,048 ▲ 8.7% | 21,545 ▲ 13.1% | 24,670 ▲ 14.5% | 28,011 ▲ 13.5% | 32,644 ▲ 16.5% | 33,700 ▲ 3.2% | |
| Sales Growth YoY %Derived | — | 8.17% | 13.39% | 8.74% | 13.11% | 14.50% | 13.54% | 16.54% | 3.24% | |
| Other Income | 155 | 338 ▲ 117.5% | 621 ▲ 83.9% | 291 ▼ 53.0% | 484 ▲ 66.2% | 1,056 ▲ 117.9% | 894 ▼ 15.3% | 1,097 ▲ 22.7% | 1,358 ▲ 23.8% | |
| Total Income | 14,436 | 15,786 ▲ 9.3% | 18,138 ▲ 14.9% | 19,339 ▲ 6.6% | 22,030 ▲ 13.9% | 25,725 ▲ 16.8% | 28,905 ▲ 12.4% | 33,741 ▲ 16.7% | 35,059 ▲ 3.9% | |
4,040 | 4,495 ▲ 11.3% | 5,554 ▲ 23.6% | 6,079 ▲ 9.4% | 7,442 ▲ 22.4% | 7,658 ▲ 2.9% | 8,209 ▲ 7.2% | 9,980 ▲ 21.6% | 12,239 ▲ 22.6% | ||
| Gross ProfitDerived | 10,242 | 10,953 ▲ 7.0% | 11,963 ▲ 9.2% | 12,969 ▲ 8.4% | 14,103 ▲ 8.7% | 17,012 ▲ 20.6% | 19,802 ▲ 16.4% | 22,664 ▲ 14.5% | 21,461 ▼ 5.3% | |
| Gross Margin %Derived | 71.71% | 70.90% | 68.29% | 68.09% | 65.46% | 68.96% | 70.69% | 69.43% | 63.68% | |
7,890 | 7,775 ▼ 1.5% | 9,492 ▲ 22.1% | 9,099 ▼ 4.1% | 10,335 ▲ 13.6% | 10,663 ▲ 3.2% | 11,869 ▲ 11.3% | 14,117 ▲ 18.9% | 15,008 ▲ 6.3% | ||
| EBITDA (Operating Profit)Derived | 2,351 | 3,178 ▲ 35.2% | 2,470 ▼ 22.3% | 3,870 ▲ 56.7% | 3,768 ▼ 2.6% | 6,349 ▲ 68.5% | 7,933 ▲ 25.0% | 8,547 ▲ 7.7% | 6,454 ▼ 24.5% | |
| OPM %Derived | 16.46% | 20.57% | 14.10% | 20.32% | 17.49% | 25.74% | 28.32% | 26.18% | 19.15% | |
1,156 | 1,224 ▲ 5.9% | 1,261 ▲ 3.1% | 1,326 ▲ 5.1% | 1,261 ▼ 4.9% | 1,393 ▲ 10.5% | 1,641 ▲ 17.8% | 1,987 ▲ 21.1% | 2,433 ▲ 22.5% | ||
| Profit Before Tax (PBT) | 1,350 | 2,292 ▲ 69.7% | 1,830 ▼ 20.2% | 2,836 ▲ 55.0% | 2,991 ▲ 5.5% | 6,012 ▲ 101.0% | 7,186 ▲ 19.5% | 7,658 ▲ 6.6% | 5,379 ▼ 29.8% | |
438 | 386 ▼ 11.9% | -140 ▼ 136.4% | 932 ▲ 764.2% | 879 ▼ 5.7% | 1,541 ▲ 75.4% | 1,623 ▲ 5.3% | 1,954 ▲ 20.4% | 1,235 ▼ 36.8% | ||
| Effective Tax %Derived | 32.43% | 16.83% | -7.67% | 32.87% | 29.38% | 25.64% | 22.59% | 25.52% | 22.96% | |
| Total Profit for Period | 947 | 1,950 ▲ 106.0% | 2,026 ▲ 3.9% | 1,952 ▼ 3.7% | 2,183 ▲ 11.8% | 4,507 ▲ 106.5% | 5,578 ▲ 23.8% | 5,725 ▲ 2.6% | 4,158 ▼ 27.4% | |
| Less: Non-controlling Interests | — | — | — | — | — | — | — | 70 | -38 ▼ 154.8% | |
| Net Profit (Owner's PAT)Derived | 947 | 1,950 ▲ 106.0% | 2,026 ▲ 3.9% | 1,952 ▼ 3.7% | 2,183 ▲ 11.8% | 4,507 ▲ 106.5% | 5,578 ▲ 23.8% | 5,655 ▲ 1.4% | 4,196 ▼ 25.8% | |
| Net Profit Margin %Derived | 6.63% | 12.62% | 11.57% | 10.25% | 10.13% | 18.27% | 19.91% | 17.32% | 12.45% | |
| PAT Growth YoY %Derived | — | 105.96% | 3.90% | -3.67% | 11.83% | 106.52% | 23.75% | 1.38% | -25.80% | |
| Earnings Per Share (EPS ₹) | 11.41 | 23.48 ▲ 105.8% | 24.38 ▲ 3.8% | 23.47 ▼ 3.7% | 26.23 ▲ 11.8% | 54.13 ▲ 106.4% | 66.87 ▲ 23.5% | 67.77 ▲ 1.3% | 50.27 ▼ 25.8% | |
| Diluted Shares Outstanding (Cr) | 83 | 83 ▲ 0.1% | 83 ▲ 0.1% | 83 ▲ 0.1% | 83 ▲ 0.1% | 83 ▲ 0.1% | 83 ▲ 0.2% | 83 ▲ 0.0% | 83 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 34 | 44 ▲ 27.3% | 56 ▲ 28.1% | 48 ▼ 14.4% | 70 ▲ 46.5% | 37 ▼ 47.4% | 15 ▼ 60.3% | 22 ▲ 47.6% | 13 ▼ 38.2% | |
| Other Comprehensive Income (Net of Tax) | -284 | -109 ▲ 61.7% | -65 ▲ 40.2% | 540 ▲ 930.8% | -290 ▼ 153.7% | -12 ▲ 95.8% | -66 ▼ 442.1% | 205 ▲ 412.3% | 740 ▲ 260.9% | |
| Total Expenses (incl. D&A & Interest) | 13,086 | 13,494 ▲ 3.1% | 16,308 ▲ 20.9% | 16,503 ▲ 1.2% | 19,039 ▲ 15.4% | 19,714 ▲ 3.5% | 21,719 ▲ 10.2% | 26,083 ▲ 20.1% | 29,679 ▲ 13.8% | |
| Material Cost % of RevenueDerived | 18.42% | 18.70% | 17.04% | 22.55% | 20.02% | 17.11% | 16.03% | 17.41% | 19.29% | |
| Employee Cost % of RevenueDerived | 22.51% | 21.73% | 19.30% | 19.06% | 18.04% | 18.84% | 17.96% | 17.09% | 17.78% | |
| Other Cost % of RevenueDerived | 32.74% | 28.61% | 34.89% | 28.71% | 29.93% | 24.39% | 24.42% | 26.15% | 26.76% | |
| Interest Coverage (x)Derived | 16.17x | 22.99x | 13.30x | 27.23x | 27.17x | 35.71x | 37.77x | 24.19x | 11.76x |
Dr Reddys Laboratories segment analysis : revenue and profit mix.
Disclosed business segments at Dr Reddys Laboratories with their share of revenue and profit, switchable between consolidated and standalone reporting.
Dr Reddys Laboratories discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Dr Reddys Laboratories Ltd.
Our AI distills the core fundamental drivers supporting Dr Reddys Laboratories Ltd, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Dr Reddys Laboratories Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust ROCE of 22.70% demonstrates efficient capital deployment and competitive positioning.
Low debt-to-equity ratio of 0.20x provides financial flexibility and reduces leverage risk.
Market cap of ₹1.01 LCr ranks among top Indian pharma peers, offering scale.
Operating margin of 14.92% TTM reflects solid operational efficiency in core business.
Stable promoter holding of 26.6% ensures long-term governance and strategic continuity.
Key Risks.
Latest quarterly EPS declined 86.2% YoY, signaling significant near-term earnings pressure.
TTM revenue declined 11.6% YoY, reflecting challenging market conditions and demand softness.
Net profit margin of 12.76% trails peer averages, indicating pricing power compression.
Capex CAGR of 26.76% over five years strains cash flow and limits shareholder returns.
Dividend yield of 0.65% remains low, offering minimal income to yield-seeking investors.
Flip Conditions.
Valuation risk. a P/E above 31 (~0.8× the sector multiple of 39.7) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Dr Reddys Laboratories Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Dr Reddys Laboratories Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Dr Reddys Laboratories Ltd chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Dr Reddys Laboratories Ltd — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Dr Reddys Laboratories Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Dr Reddys Laboratories Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Dr Reddys Laboratories Ltd stood at 53.0% of traded volume, against a 20-day average of 48.9%.
Dr Reddys Laboratories announcements: results, concalls, ratings, M&A.
Filings Dr Reddys Laboratories sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Dr Reddys Laboratories files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 204 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Dr. Reddy's Laboratories Limited has informed the Exchange about Link of Recording
Analysts/Institutional Investor Meet/Con. Call Updates
Dr. Reddy's Laboratories Limited has informed the Exchange about Conference Call
General Updates
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Dr. Reddy's Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Copy of Newspaper Publication
Dr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
Dr Reddys Laboratories dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Dr Reddys Laboratories has declared, sequenced by announce and record date.
Dr Reddys Laboratories corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Dr Reddys Laboratories insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Dr Reddys Laboratories as reported to SEBI — buying and selling signals from the people who know the business best.
Dr Reddys Laboratories insider activity below tracks 6 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Patrick Aghanian | Insider | 26 Mar 2026 | buy | +3.7 K | ₹47.84 L | ₹1,301.90 |
| Patrick Aghanian | Insider | 26 Mar 2026 | buy | +3.7 K | ₹47.84 L | ₹1,301.90 |
| Patrick Aghanian | Insider | 26 Mar 2026 | buy | +3.7 K | ₹47.84 L | ₹1,301.90 |
| Patrick Aghanian | Insider | 26 Mar 2026 | buy | +3.7 K | ₹47.84 L | ₹1,301.90 |
| Patrick Aghanian | Insider | 26 Mar 2026 | buy | +3.7 K | ₹47.84 L | ₹1,301.90 |
| Patrick Aghanian | Insider | 26 Mar 2026 | buy | +3.7 K | ₹47.84 L | ₹1,301.90 |
About Dr Reddys Laboratories Ltd: business, sector, key facts.
What Dr Reddys Laboratories Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Dr Reddys Laboratories Ltd operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: DRREDDY, BSE: 500124.
Dr. Reddy's Laboratories Limited (DRREDDY) is a global integrated pharmaceutical company with a diverse business model spanning various segments and therapeutic areas. The company's primary focus lies in the research, development, manufacturing, and marketing of pharmaceutical products worldwide. Its operations extend across the entire value chain, from the production of active pharmaceutical ingredients (APIs) to the manufacturing and marketing of finished dosage forms.
A significant portion of DRREDDY's business is driven by its Global Generics segment. This segment focuses on producing and distributing both branded and generic finished pharmaceutical products. These products cover a wide range of therapeutic categories, ensuring market presence across various disease areas and patient needs. The company's commitment to generic medications provides affordable access to essential medicines globally.
The Pharmaceutical Services and Active Ingredients (PSAI) segment plays a crucial role in the company's overall strategy. It manufactures and markets APIs and intermediates, which are essential components in the production of finished dosage forms. Beyond this, PSAI also provides contract research services, catering to the needs of other pharmaceutical companies and further diversifying its revenue streams. The segment's capabilities in API manufacturing allows for both internal use and external sales, enhancing its position in the pharmaceutical supply chain.
Beyond its core generics and API businesses, DRREDDY also operates an "Others" segment. This segment is dedicated to research and development activities, primarily focused on developing novel therapies in oncology and inflammation. This investment in innovation highlights DRREDDY's long-term strategy of creating differentiated and potentially higher-value products to complement its existing generics portfolio. This aspect reflects DRREDDY's intention to be a player in both established markets and emerging therapeutic fields.
In summary, DRREDDY's business model is characterized by its integrated approach, encompassing the entire pharmaceutical value chain from API manufacturing to finished product marketing. Its operations cover a broad spectrum of therapeutic areas and leverage a mix of generic and innovative products. The company’s focus on both established and emerging markets, coupled with its commitment to research and development, positions it for continued growth and expansion in the global pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Dr Reddys Laboratories Ltd (DRREDDY).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Dr Reddys Laboratories Ltd (DRREDDY)?
The current share price of Dr Reddys Laboratories Ltd (DRREDDY) is ₹1,211.2. Today, the stock has declined by ₹13.20 (1.08%), trading in a range of ₹1,201.2 to ₹1,229.9. The stock opened at ₹1,227.5 with a trading volume of 20,75,149 shares.
02Is Dr Reddys Laboratories Ltd stock a good investment for long-term?
Dr Reddys Laboratories Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,01,160.42 crores, P/E ratio of 24.09, ROE of 11.20%, and ROCE of 13.00%. The dividend yield stands at 0.65%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Dr Reddys Laboratories Ltd stock?
The 52-week high price of Dr Reddys Laboratories Ltd (DRREDDY) is ₹1,414.9, while the 52-week low is ₹1,148.4. Currently trading at ₹1,211.2, the stock is 23.6% away from its 52-week low and 14.4% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Dr Reddys Laboratories Ltd stock at the current price?
Whether to buy Dr Reddys Laboratories Ltd stock at ₹1,211.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 24.09 and P/B ratio of 2.67. Today's performance shows a loss of 1.08%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Dr Reddys Laboratories Ltd and when is the next dividend?
Dr Reddys Laboratories Ltd offers a dividend yield of 0.65%, which means for every ₹100 invested at the current price of ₹1,211.2, you can expect to receive approximately ₹0.65 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd's key financial metrics include: P/E Ratio: 24.09, P/B Ratio: 2.67, ROE: 11.20%, ROCE: 13.00%, Dividend Yield: 0.65%, EPS: ₹50.30, Book Value: ₹454, and Debt-to-Equity: 0.20. The company's market cap stands at ₹1,01,160.42 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Dr Reddys Laboratories Ltd stock performing today in the market?
Dr Reddys Laboratories Ltd stock opened at ₹1,227.5 and is currently trading at ₹1,211.2, showing a decline of ₹13.20 (1.08%). The intraday high is ₹1,229.9 and low is ₹1,201.2. The trading volume stands at 20,75,149 shares, indicating strong market participation today.
08What is the P/E ratio of Dr Reddys Laboratories Ltd and what does it indicate?
Dr Reddys Laboratories Ltd has a Price-to-Earnings (P/E) ratio of 24.09, which means investors are willing to pay ₹24.09 for every ₹1 of earnings. With an EPS of ₹50.30, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Dr Reddys Laboratories Ltd (DRREDDY) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.